

INVERNESS MEDICAL INNOVATIONS INC

Form 8-K

June 10, 2003

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) June 6, 2003**

**Inverness Medical Innovations, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or other jurisdiction of  
incorporation)

**001-16789**

(Commission file number)

**04-3565120**

(IRS Employer Identification  
No.)

**51 Sawyer Road, Suite 200, Waltham, Massachusetts 02453**

(Address of principal executive offices)

Registrant's telephone number, including area code: **(781) 647-3900**

**Not Applicable**

(Former name or former address, if changed since last report)

**ITEM 5. OTHER EVENTS**

On June 6, 2003, we entered into a settlement agreement with a subsidiary of Pfizer, Inc. which resolves all of our patent infringement claims against Pfizer. In connection with the settlement one of our subsidiaries, Unipath, Ltd., has entered into a five year supply arrangement with Pfizer to supply its U.S. market leader E.P.T.® pregnancy tests, beginning in June, 2004. A copy of our press release dated June 9, 2003 announcing the settlement and supply arrangement is attached as Exhibit 99.1 to this Current Report on Form 8 K and incorporated by reference herein.

**ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS**

c)

Exhibits. The following exhibits are filed with this document.

| <b>Exhibit<br/>Number</b> | <b>Description</b>  |
|---------------------------|---|
| 99.1                      | Press Release dated June 9, 2003, entitled Inverness Medical Innovations Announces Settlement with Pfizer and Conference Call to discuss the Settlement |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INVERNESS MEDICAL INNOVATIONS, INC.

BY: /s/ Paul T. Hempel  
Paul T. Hempel  
General Counsel & Secretary

Dated: June 10, 2003

**EXHIBIT INDEX**

| <b>Exhibit<br/>Number</b> | <b>Description</b>  |
|---------------------------|---|
| 99.1                      | Press Release dated June 9, 2003, entitled Inverness Medical Innovations Announces Settlement with Pfizer and Conference Call to discuss the Settlement |